Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans
| Autor: | A R Tunkel, J Harris, Frederick G. Hayden, S Allerheiligen, R F Betts, John J. Treanor |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent viruses Orthomyxoviridae Antibodies Viral medicine.disease_cause Placebo Antiviral Agents Gastroenterology Asymptomatic Virus Cell Line Dogs Double-Blind Method Internal medicine Influenza Human Nitriles Thiadiazoles Influenza A virus Animals Humans Medicine Pharmacology (medical) Viral shedding Pharmacology biology business.industry Hemagglutination Inhibition Tests Middle Aged Nasal Lavage Fluid biology.organism_classification Titer Infectious Diseases medicine.anatomical_structure Immunology medicine.symptom business Research Article Respiratory tract |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 38:1178-1181 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.38.5.1178 |
| Popis: | The efficacy and safety of oral LY217896 for prevention of experimental influenza A/Kawasaki/86 (H1N1) virus infection were assessed in susceptible males randomly assigned to receive LY217896 (75 mg) or placebo once daily for 7 days beginning 24 h prior to viral challenge. The rates of virus shedding (100% in both groups), days of viral shedding (3.1 +/- 1.3 for the LY217896 group; 2.8 +/- 1.3 for the placebo group), and titers of virus in nasal washings did not differ between the groups. Mild upper respiratory tract illness (72% in the LY217896 group; 69% in the placebo group) developed in similar proportions of each group. LY217896 was associated with asymptomatic rises in serum uric acid levels and was ineffective in modifying the virologic or clinical course of experimental influenza A (H1N1) virus infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|